Shanghai GenePharma Co., Ltd. signed a non-exclusive worldwide license to use the Kreutzer-Limmer siRNA patents belonging to Alnylam Pharmaceuticals. The license, which is the first transaction Alnylam has signed with a China biotech, covers the right to manufacture and provide RNAi research products and services. GenePharma will manufacture RNAi reagent products for research use in China and worldwide. More details...

Stock Symbol: (NSDQ: ALNY)